Venous thrombosis: A multicausal disease

Lancet

Volumn 353, Issue 9159, 1999, Pages 1167-1173

  Rosendaal, F R ^a  

^a LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

BLOOD CLOTTING FACTOR; BLOOD CLOTTING FACTOR 5; ORAL CONTRACEPTIVE AGENT; PROTEIN C;

ARTERY DISEASE; BLOOD CLOTTING DISORDER; BLOOD GROUP ABO SYSTEM; ENVIRONMENTAL FACTOR; HEREDITY; HUMAN; INCIDENCE; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; PROTEIN C DEFICIENCY; REVIEW; RISK FACTOR; THROMBOGENESIS; VEIN THROMBOSIS;

EID: 0033519051     PISSN: 01406736     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0140-6736(98)10266-0     Document Type: Review

References (76)

1. Nordström M., Lindblad B., Bergqvist D., Kjellström T. A prospective study of the incidence of deep-vein thrombosis with a defined urban population. J Intern Med. 232:1992;155-160.
2. Anderson F.A., Wheeler H.B., Goldberg R.J.et al. A population based perspective of the hospital incidence and case-fatality rates of deep vein thrombosis and pulmonary embolism. The Worcester DVT study. Arch Intern Med. 151:1991;933-938.
3. Rosendaal F.R. Thrombosis in the young: epidemiology and risk factors, a focus on venous thrombosis. Thromb Haemost. 78:1997;1-6.
4. Carter C.J. The natural history and epidemiology of venous thrombosis. Prog Cardiovasc Dis. 36:1994;423-438.
5. Thomas D.P. Pathogenesis of venous thombosis. Bloom A.L., Forbes C.D., Thomas D.P., Tuddenham E.G.D. Haemostasis and thrombosis. 1994;1335-1347 Churchill-Livingstone, New York.
6. Brandjes D.P., Büller H.R., Heijboer H.et al. Randomised trial of effect of compression stockings in patients with symptomatic proximal-vein thrombosis. Lancet. 349:1997;759-762.
7. Virchow R. Phlogose und Thrombose im Gefässystem. In: Gesammelte Abhandlungen zur Wissenschaftlichen Medizin. Frankfurt: Staatsdruckerei, 1856.
8. Egeberg O. Inherited antithrombin deficiency causing thrombophilia. Thromb Diath Haemorrh. 13:1965;516-530.
9. Griffin J.H., Evatt B., Zimmerman T.S., Kleiss A.J., Wideman C. Deficiency of protein C in congenital thrombotic disease. J Clin Invest. 68:1981;1370-1373.
10. Schwartz H.P., Fischer M., Hopmeier P., Batard M.A., Griffin J.H. Plasma protein S deficiency in familial thrombotic disease. Blood. 64:1984;1297-1300.
11. Dahlbäck B., Carlsson M., Svensson P.J. Familial thrombophilia due to a previously unrecognised mechanism characterized by poor anticoagulant response to activated protein C: prediction of a cofactor to activated protein C. Proc Natl Acad Sci USA. 90:1993;1004-1008.
12. Bertina R.M., Koeleman R.P.C., Koster T.et al. Mutation in blood coagulation factor V associated with resistance to activated protein C. Nature. 369:1994;64-67.
13. Mannucci P.M., Tripodi A., Botasso B.et al. Markers of procoagulant imbalance in patients with inherited thrombophilic syndromes. Thromb Haemost. 67:1992;200-202.
14. Poort S.R., Rosendaal F.R., Reitsma P.H., Bertina R.M. A common genetic variation in the 3′-untranslated region of the prothrombin gene is associated with elevated plasma prothrombin levels and an increase in venous thrombosis. Blood. 88:1996;3698-3703.
15. Koster T., Blann A.D., Briët E., Vandenbrouke J.P., Rosendaal F.R. Role of clotting factor VIII in effect of von Willebrand factor on occurrence of deep-vein thrombosis. Lancet. 345:1995;152-155.
16. Jick H., Slone D., Westerholm B.et al. Venous thromboembolic disease and ABO blood type. Lancet. i:1969;539-542.
17. Kamphuisen P.W., Houwing-Duistermaat J.J., van Houwelingen J.C.et al. Familial clustering of factor VIII and von Willebrand factor levels. Thromb Haemost. 79:1998;323-327.
18. Mansvelt E.P.G., Laffan M., McVey J.H., Tuddenham E.G.D. Analysis of the F8 gene in individuals with high plasma factor VIII:C levels and associated venous thrombosis. Thromb Haemost. 80:1998;561-565.
19. Balleisen L., Bailey J., Epping P.H., Schulte H., van de Loo J. Epidemiological study on factor V.I.I., factor VIII and fibrinogen in an industrial population.I. Baseline data on the relation to age, gender, body-weight, smoking, alcohol, pill-using, and menopause. Thromb Haemost. 54:1985;475-479.
20. Balleisen L., Assman G., Bailey J., Epping P.H., Schulte H., van de Loo J. Epidemiological study on factor V.I.I., factor VIII and fibrinogen in an industrial population.I.I. Baseline data on the relation of blood pressure, blood glucose, uric acid, and lipid fractions. Thromb Haemost. 54:1985;721-723.
21. Lowe G.D., Rumley A., Woodward M.et al. Epidemiology of coagulation factors, inhibitors and activation markers: the Third Glasgow MONICA Survey.I. Illustrative reference ranges by age, sex, and hormone use. Br J Haematol. 97:1997;775-784.
22. Bloemenkamp K.W.M., Rosendaal F.R., Helmerhorst F.M., Koster T., Bertina R.M., Vandenbroucke J.P. Hemostatic effects of oral contraceptives in women who developed deep-vein thrombosis while using oral contraceptives. Thromb Haemost. 80:1998;382-387.
23. Bienvenu T., Ankri A., Chadefaux B., Kamoun P. Plasma homocystein assay in the exploration of thrombosis in young subjects. Presse Medicale. 20:1991;985-988.
24. Falcon C.R., Cattaneo M., Panzeri D., Martinelli I., Mannucci P.M. High prevalence of hyperhomocyst(e)inemia in patients with juvenile venous thrombosis. Arterioscler Thromb. 14:1994;1080-1083.
25. Simioni P., Prandoni P., Burlina A.et al. Hyperhomocysteinemia and deep-vein thrombosis: a case-control study. Thromb Haemost. 76:1996;883-886.
26. Den Heijer M., Koster T., Blom H.J.et al. Hyperhomocysteinemia as a risk factor for deep-vein thrombosis. N Engl J Med. 334:1996;759-762.
27. Den Heijer M., Rosendaal F.R., Blom H.J., Gerrits W.B.J., Bos G.M.J. Hyperhomocysteinemia and venous thrombosis: a meta-analysis. Thromb Haemost. 80:1998;874-877.
28. Fermo I., D'Angelo S.V., Paroni R., Mazzola G., Calori G., D'Angelo A. Prevalence of moderate hyperhomocysteinemia in patients with early-onset venous and arterial occlusive disease. Ann Intern Med. 123:1995;747-753.
29. Ubbink J.B., Vermaak W.J., Van der Merwe A., Becker P.J. Vitamin B12, vitamin B6, and folate nutritional status in men with hyperhomocysteinemia. Am J Clin Nutr. 57:1993;47-53.
30. Rosendaal F.R. Risk factors for venous thrombosis: prevalence, risk and interaction. Semin Hematol. 34:1997;171-187.
31. Tait R.C., Walker I.D., Reitsma P.H.et al. Prevalence of protein C deficiency in the healthy population. Thromb Haemost. 73:1995;87-93.
32. Tait R.C., Walker I.D., Perry D.J.et al. Prevalence of antithrombin deficiency in the healthy population. Br J Haematol. 87:1994;106-112.
33. Miletich J., Sherman L., Broze G. Absence of thrombosis in subjects with heterozygous protein C deficiency. N Engl J Med. 317:1987;991-996.
34. Rosendaal F.R., Koster T., Vandenbroucke J.P., Reitsma P.H. High risk of thrombosis in patients homozygous for factor V Leiden (activated protein C resistance). Blood. 85:1995;1504-1508.
35. Koster T., Rosendaal F.R., Briët E.et al. Protein C deficiency in a controlled series of unselected outpatients: an infrequent but clear risk factor for venous thrombosis (Leiden Thrombophilia Study). Blood. 85:1995;2756-2761.
36. Lane D.A., Mannucci P.M., Bauer K.A.et al. Inherited thrombophilia: part 1. Thromb Haemost. 76:1996;651-662.
37. Rees D.C., Cox M., Clegg J.B. World distribution of factor V Leiden. Lancet. 346:1995;1133-1134.
38. Koster T., Rosendaal F.R., De Ronde H., Briët E., Vandenbroucke J.P., Bertina R.M. Venous thrombosis due to a poor anticoagulant response to activated protein C: Leiden Thrombophilia Study. Lancet. 342:1993;1503-1506.
39. Rosendaal F.R., Doggen C.J.M., Zivelin A.et al. Geographic distribution of the 20210 G to A prothrombin variant. Thromb Haemost. 79:1998;706-708.
40. Andrew M., David M., Adams M.et al. Venous thromboembolic complications (VTE) in children: first analyses of the Canadian registry. Blood. 83:1994;1251-1257.
41. Nuss R., Hays T., Manco-Johnson M. Childhood thrombosis. Pediatrics. 96:1995;291-294.
42. Tabernero M.D., Tomas J.F., Alberca I., Orfao A., Lopez Borrasca A., Vicente V. Incidence and clinical characteristics of hereditary disorders associated with venous thrombosis. Am J Hematol. 36:1991;249-254.
43. Griffin J.H., Evatt B., Wideman C., Fernandez J.A. Anticoagulant protein C pathway defective in a majority of thrombophilic patients. Blood. 82:1993;1989-1993.
44. Scharrer I., Hach-Wunderle V., Heyland H., Kuhn C. Incidence of defective t-PA release in 158 unrelated young patients with venous thrombosis in comparison to PC-, PS-, AT III-, fibrinogen- and plasminogen deficiency. Thromb Haemost. 58:1987;72.
45. Ben Tal O., Zivelin A., Seligsohn U. The relative frequency of hereditary thrombotic disorders among 107 patients with thrombophilia in Israel. Thromb Haemost. 61:1989;50-54.
46. Allaart C.F., Poort S.R., Rosendaal F.R., Reitsma P.H., Bertina R.M., Briët E. Increased risk of venous thrombosis in carriers of protein C deficiency defect. Lancet. 341:1993;134-138.
47. Tsuda S., Reitsma P., Miletich J. Molecular defects causing heterozygous protein C deficiency in three asymptomatic kindreds. Thromb Haemost. 65:1991;647.
48. Lensen R.P.M., Rosendaal F.R., Koster T.et al. Apparent different thrombotic tendency in patients with factor V Leiden and protein C deficiency due to selection of patients. Blood. 88:1996;4205-4208.
49. Koeleman B.P.C., Reitsma P.H., Allaart C.F., Bertina R.M. APC-resistance as an additional risk factor for thrombosis in protein C deficient families. Blood. 84:1994;1031-1035.
50. Zöller B., Berntsdotter A., Garcia de Frutos P., Dahlbäck B. Resistance to activated protein C as an additional genetic risk factor in hereditary deficiency of protein S. Blood. 85:1995;3518-3523.
51. Van Boven H.H., Reitsma P.H., Rosendaal F.R.et al. Factor V Leiden (FV R506Q) in families with inherited antithrombin deficiency. Thromb Haemost. 75:1996;417-421.
52. Makris M., Preston F.E., Beauchamp N.J.et al. Co-inheritance of the 20210A allele of the prothrombin gene increases the risk of thrombosis in subjects with familial thrombophilia. Thromb Haemost. 170:1997;1426-1429.
53. Branson H.E., Marble R., Katz J., Griffin J.H. Inherited protein C deficiency and coumarin-responsive chronic relapsing purpura fulminans in a newborn. Lancet. ii:1983;1165-1168.
54. Mahasandana C., Suvatte V., Chuansumrit A.et al. Homozygous protein S deficiency in an infant with purpura fulminans. J Pediatr. 117:1990;750-753.
55. Hakten M., Deniz U., Ozbag G., Ulutin O.N. Two cases of homozygous antithrombin III deficiency in a family with congenital deficiency of ATIII. Senzinger H., Vinazzer H. Thrombosis and haemorrhagic disorders. 1989;177-181 Schmitt und Meyer GmbH, Wurzberg.
56. Rintelen C., Mannhalter C., Ireland H.et al. Oral contraceptives enhance the risk of clinical manifestation of venous thrombosis at a young age in females homozygous for factor V Leiden. Br J Haematol. 93:1996;487-490.
57. Kyrle P.A., Mannhalter C., Béguin S.et al. Clinical studies and thrombin generation in patients homozygous or heterozygous for the G20210A mutation in the prothrombin gene. Arterioscler Thromb Vasc Biol. 18:1998;1287-1291.
58. Conard J., Horellou M.H., Van Dreden P., Lecompte T., Samama M. Thrombosis and pregnancy in congenital deficiencies in AT III, protein C or protein S: study of 78 women. Thromb Haemost. 63:1990;319-320.
59. Pabinger I., Schneider B. Thrombotic risk of women with hereditary antithrombin III-, protein C and protein S-deficiency taking oral contraceptive medication. Thromb Haemost. 71:1994;548-552.
60. De Stefano V., Leone G., Mastrangelo S.et al. Thrombosis during pregnancy and surgery in patients with congenital deficiency of antithrombin III, protein C, protein S. Thromb Haemost. 74:1995;793-794.
61. Hellgren M., Tengborn L., Abildgaard U. Pregnancy in women with congenital antithrombin III deficiency: experience of treatment with heparin and antithrombin. Gynecol Obstet Invest. 14:1982;127-141.
62. Freiderich P.W., Sanson B.J., Simioni P.et al. Frequency of pregnancy-related venous thromboembolism in anticoagulant factor-deficient women: implications for prophylaxis. Ann Intern Med. 125:1996;955-960.
63. Bokarewa M.I., Bremme K., Blomback M. Arg506-Gln mutation in factor V and risk of thrombosis during pregnancy. Br J Haematol. 92:1996;473-478.
64. Hellgren M., Svensson P.J., Dahlbäck B. Resistance to activated protein C as a basis for venous thromboembolism associated with pregnancy and oral contraceptives. Am J Obstet Gynecol. 173:1995;210-215.
65. Hirsh D.R., Mikkola K.M., Marks P.W.et al. Pulmonary embolism and deep venous thrombosis during pregnancy or oral contraceptive use: prevalence of factor V Leiden. Am Heart J. 131:1996;1145-1148.
66. McColl M.D., Ramsay J.E., Tait R.C.et al. Risk factors for pregnancy associated venous thromboembolism. Throm Haemost. 78:1997;1183-1188.
67. Vandenbroucke J.P., Koster T., Briët E., Reitsma P.H., Bertina R.M., Rosendaal F.R. Increased risk of venous thrombosis in oral-contraceptive users who are carriers of factor V Leiden mutation. Lancet. 344:1994;1453-1457.
68. deBruijn S.F., Stam J., Koopman M.M., Vandenbroucke J.P. Case-control study of risk of cerebral sinus thrombosis in oral contraceptive users who are carriers of hereditary prothrombotic conditions. BMJ. 316:1998;589-592.
69. Martinelli I., Sacchi E., Landi G., Taioli E., Duca F., Mannucci P.M. High risk of cerebral-vein thrombosis in carriers of the prothrombin-gene mutation and in users of oral contraceptives. N Engl J Med. 338:1998;1793-1797.
70. Bertina R.M., Reitsma P.H., Rosendaal F.R., Vandenbroucke J.P. Resistance to activated protein C and factor V Leiden as risk factors for venous thrombosis. Thromb Haemost. 74:1995;449-453.
71. Broekmans A.W., Van der Linden I.K., Veltkamp J.J., Bertina R.M. Prevalence of isolated protein C deficiency in patients with venous thrombotic disease and in the population. Thromb Haemost. 50:1983;350. abstr.
72. Miletich J.P., Prescott S.M., White R., Majerus P.W., Bovill E.G. Inherited predisposition to thrombosis. Cell. 72:1993;477-480.
73. Reitsma P.H., Poort S.R., Allaart C.F., Briët E., Bertina R.M. The spectrum of genetic defects in a panel of 40 Dutch families with symptomatic protein C deficiency type I: heterogeneity and founder effects. Blood. 78:1991;890-894.
74. Nordling C.O. A new theory on the cancer inducing mechanism. Br J Cancer. 7:1953;68-72.
75. Siemiatycki J., Thomas D.C. Biological models and statistical interactions: an example from multistage carcinogenesis. Int J Epidemiol. 10:1981;383-387.
76. Rosing J., Tans G., Nicolaes G.A.et al. Oral contraceptives and venous thrombosis: different sensitivities to activated protein C in women using second- and third-generation oral contraceptives. Br J Haematol. 97:1997;233-238.